Inadequate Health Insurance Coverage: A Major Factor in Premature Discontinuation of Subcutaneous Immunotherapy for Allergic Rhinitis

Subcutaneous Immunotherapy and Synbiotic Combination Shift T-Helper 1 and Cytotoxic T Cells in Allergic Rhinitis

Background: Synbiotics have been used in the prevention and treatment of various immunological diseases. We aimed to investigate the synergistic clinical and immunologic effects of synbiotics and subcutaneous allergen immunotherapy (SCIT) combination in patients with allergic rhinitis. Materials and Methods: Nineteen individuals with all...

Efficacy and Safety of Subcutaneous Allergen Immunotherapy for Allergic Rhinitis

Safety of specific subcutaneous immunotherapy in patients with allergic rhinitis

Methods We conducted a retrospective, longitudinal study evaluating patients with AR, over the age of three, who were using SCIT with extracts of D pteronyssinus (Dp) and/or B tropicalis (Bt) (FDA Allergenic). Data were collected through interviews and medical records. The classification of the severity of adverse reactions met the criteria established by the Allergen Immunotherapy: a Practice ...

Immunotherapy for allergic rhinitis.

Allergic rhinitis (AR) affects more than 20% of the population in the United Kingdom and western Europe and represents a major cause of morbidity that includes interference with usual daily activities and impairment of sleep quality. This guidance prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) is for the management of AR in ...

Immunotherapy for Allergic Rhinitis

Successful treatment of allergic diseases depends on the correct identification of clinically relevant allergens. This is often accomplished with a detailed clinical and environmental history, aided by laboratory tests to confirm sensitization and environmental allergen analysis. The importance of allergen avoidance or elimination cannot be over-emphasized. While complete elimination of allerge...